5 results on '"Moreno, Esther"'
Search Results
2. A prospective study of costs associated to the evaluation of non‐steroidal anti‐inflammatory hypersensitivity reactions.
- Author
-
Sobrino‐García, Miriam, Muñoz‐Bellido, Francisco J., Moreno, Esther, Macías, Eva, Gracia‐Bara, María‐Teresa, Laffond, Elena, Lázaro‐Sastre, Milagros, Martín‐García, Cristina, Arriba‐Méndez, Sonia, Campanón‐Toro, María‐Valle, Gallardo‐Higueras, Alicia, and Dávila, Ignacio
- Subjects
- *
LONGITUDINAL method , *ALLERGIES , *URTICARIA - Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most frequent causes of drug hypersensitivity reactions, affecting 1%-3% of general population; the prevalence of NSAID hypersensitivity is higher in patients with chronic rhinosinusitis, nasal polyposis, asthma, or chronic urticaria, affecting up to 30% of patients[1]. This is a prospective, real-life, observational study aimed to evaluate all direct and indirect health costs of patients that consulted in our outpatient clinic for suspected NSAID hypersensitivity reactions. One of the advantages of performing a study of NSAID hypersensitivity is de-labeling of purported NSAID hypersensitivity patients. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
3. Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity.
- Author
-
Torres, María José, Trautmann, Axel, Böhm, Ingrid, Scherer, Kathrin, Barbaud, Annick, Bavbek, Sevim, Bonadonna, Patrizia, Cernadas, Josefina Rodrigues, Chiriac, Anca Mirela, Gaeta, Francesco, Gimenez‐Arnau, Ana M., Kang, Hye‐Ryun, Moreno, Esther, and Brockow, Knut
- Subjects
- *
CONTRAST media , *ALLERGIES , *DIAGNOSIS , *RISK assessment , *CLINICAL drug trials - Abstract
Immediate and nonimmediate hypersensitivity reactions to iodinated contrast media (ICM) have been reported to occur in a frequency of about 0.5%‐3% of patients receiving nonionic ICM. The diagnosis and management of these patients vary among guidelines published by various national and international scientific societies, with recommendations ranging from avoidance or premedication to drug provocation test. This position paper aims to give recommendations for the management of patients with ICM hypersensitivity reactions and analyze controversies in this area. Skin tests are recommended as the initial step for diagnosing patients with immediate and nonimmediate hypersensitivity reactions; besides, they may also help guide on tolerability of alternatives. Re‐exposition or drug provocation test should only be done with skin test‐negative ICMs. The decision for performing either re‐exposition or drug provocation test needs to be taken based on a risk‐benefit analysis. The role of in vitro tests for diagnosis and pretreatment for preventing reactions remains controversial. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Recent developments and highlights in drug hypersensitivity.
- Author
-
Mayorga, Cristobalina, Fernandez, Tahia D., Montañez, Maria Isabel, Moreno, Esther, and Torres, María José
- Subjects
- *
DRUG development , *DRUG side effects , *DRUG labeling , *ALLERGIES , *TRAINING needs - Abstract
Drug hypersensitivity reactions (DHRs) are nowadays the third cause of allergy after rhinitis and asthma with a significant increase in prevalence in both adults and paediatric population with new drugs included as culprit. For this, DHRs represent not only a health problem but also a significant financial burden for affected individuals and health systems. Mislabelling DHRs is showing to be a relevant problem for both, false label of drug allergic and false label of nonallergic. All this reinforces the need to improve accurate diagnostic approaches that allow an appropriate management. Moreover, there is a need for training both, nonallergist stakeholders and patients to improve the reaction identification and therefore decrease the mislabelling. The use of allergy cards has shown to be relevant to avoid the induction of DHRs due to the prescription of wrong medication. Recent developments over the last 2 years and highlights about risk factors, diagnostic approaches, mechanisms involved as well as prevention actions, and management have been reviewed. In these papers, it has been outlined the need for correct diagnosis and de‐labelling of patients previously false‐reported as allergic, which will improve the management and treatment of patients with DHRs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Interleukin-4 (IL4) and Interleukin-4 receptor (IL4RA) polymorphisms in asthma: a case control study.
- Author
-
Isidoro-García, María, Dávila, Ignacio, Laffond, Elena, Moreno, Esther, Lorente, Félix, and González-Sarmiento, Rogelio
- Subjects
- *
INTERLEUKINS , *INTERLEUKIN-4 , *IMMUNOGLOBULIN E , *IMMUNODEFICIENCY , *IMMUNE complex diseases , *IMMUNOLOGIC diseases , *ALLERGIES , *THERAPEUTICS - Abstract
Background: IL4/IL4RA pathway plays an important role in atopy and asthma. Different polymorphisms in IL4 and IL4RA genes have been described. Particularly, -33C>TIL4 and 576Q>RIL4RA SNPs have been independently associated to atopy and asthma. The purpose of this study was to analyse these polymorphisms in a population of patients with a well-characterized asthma phenotype. Methods: A total of 212 unrelated Caucasian individuals, 133 patients with asthma and 79 healthy subjects without symptoms or history of asthma or atopy and with negative skin prick tests were recruited. Lung function was measured by spirometry and asthma was specialist physician-diagnosed according to the ATS (American Thoracic Society) criteria and classified following the GINA (Global Initiative for Asthma) guidelines. Skin prick tests were performed according to EAACI recommendations. -33C>TIL4 was studied with TaqMan assay and 576Q>RIL4RA by PCR-RFLP technique. Hardy-Weinberg equilibrium was analysed in all groups. Dichotomous variables were analysed using ?2, Fisher exact test, Monte Carlo simulation test and odds ratio test. To model the effects of multiple covariates logistic regression was used. Results: No statistically significant differences between the group of patients with asthma and the controls were found when the allele and genotype distribution of -33C>TIL4 and 576Q>RIL4RA polymorphisms were compared. However, the T allele of the -33C>TIL4 SNP was more frequent in patients with persistent asthma. Multivariate analysis adjusted for age and sex confirmed that carriers of allele T had an increased risk of persistent asthma (OR:2.77, 95%CI:1.18-6.49; p = 0.019). Analysis of combination of polymorphisms showed that patients carrying both the T allele of -33C>TIL4 and the A allele of 576Q>RIL4RA had an increased risk of asthma. This association was particularly observed in persistent asthma [Fisher's p value = 0.0021, Monte Carlo p value (after 104 simulations) = 0.0016, OR:3.39; 95% CI:1.50-7.66]. Conclusion: Our results show a trend of association between the genetic combination of the T allele of -33C>TIL4 and the A allele of 576Q>RIL4RA with asthma. This genetic variant was more frequently observed in patients with persistent asthma. As long as this study was performed in a small population, further studies in other populations are needed to confirm these results. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.